Abbott Laboratories (ABT) vs GSK (GSK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GSK (GSK) has outperformed Abbott Laboratories (ABT) over the past year, gaining 7.4% versus a loss of 26.6%. Over five years, GSK leads with a +19.3% price change compared with -16.2% for ABT. Abbott Laboratories is the larger company by market cap ($170.43 billion vs $93.24 billion), about 1.8 times the size.
On valuation, GSK trades at a lower forward P/E (9.4x vs 16.2x for Abbott Laboratories). Abbott Laboratories offers the higher dividend yield (2.52% vs 1.46%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABT | GSK |
|---|---|---|
| Share price | $98.49 | $46.54 |
| Market cap | $170.43B | $93.24B |
| 1-day change | -0.24% | -1.02% |
| YTD return | -21.39% | -5.10% |
| 1-year return | -26.65% | +7.36% |
| 5-year return | -16.17% | +19.30% |
| P/E ratio (TTM) | 31.87 | 14.68 |
| Forward P/E | 16.24 | 9.42 |
| EPS (TTM) | $3.09 | $3.17 |
| Dividend yield | 2.52% | 1.46% |
| Annual dividend | $2.48 | $0.68 |
| Revenue (latest FY) | $44.33B | — |
| Revenue growth (YoY) | +5.67% | — |
| Net income (latest FY) | $6.52B | — |
| Gross margin | 56.42% | — |
| Operating margin | 18.17% | — |
| Net margin | 14.72% | — |
| 52-week high | $134.50 | $61.70 |
| 52-week low | $81.97 | $42.85 |
| Distance from 52-week high | -26.77% | -24.57% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +22.57% | +27.48% |
| Average volume | 9.64M | 3.85M |
| Shares outstanding | 1.73B | 2.00B |
| Employees | 122,000 | 66,841 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GSK has outperformed ABT by 34.0 percentage points over the past year.
- Abbott Laboratories trades at a higher earnings multiple (31.9x vs 14.7x trailing P/E).
- Abbott Laboratories offers a meaningfully higher dividend yield (2.52% vs 1.46%).
About Abbott Laboratories
ABT stock →Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Health Care · Biotechnology: Pharmaceutical Preparations · 122,000 employees
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
ABT vs GSK FAQ
Which is bigger, Abbott Laboratories or GSK?
Abbott Laboratories (ABT) is larger, with a market capitalization of $170.43B compared with $93.24B for GSK (GSK).
Which stock has performed better over the past year, ABT or GSK?
GSK returned +7.36% over the past 12 months, compared with -26.65% for ABT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABT or GSK?
GSK has the lower trailing P/E at 14.7, versus 31.9 for ABT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Abbott Laboratories or GSK?
Abbott Laboratories has the higher yield at 2.52%, compared with 1.46% for GSK.
Are Abbott Laboratories and GSK in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.